Next Article in Journal
Circulating Extracellular Vesicles Are Increased in Newly Diagnosed Celiac Disease Patients
Next Article in Special Issue
Effect of Gestational Weight Gain during the First Half of Pregnancy on the Incidence of GDM, Results from a Pregnant Cohort in Northern Greece
Previous Article in Journal
Associations of Lipids and Lipid-Lowering Drugs with Risk of Vascular Dementia: A Mendelian Randomization Study
Previous Article in Special Issue
Glucagon-like Peptide 1 Receptor Activation Inhibits Microglial Pyroptosis via Promoting Mitophagy to Alleviate Depression-like Behaviors in Diabetic Mice
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Nutrients
Volume 15
Issue 1
10.3390/nu15010072
nutrients-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Association of Non-Dipping Blood Pressure Patterns with Diabetic Peripheral Neuropathy: A Cross-Sectional Study among a Population with Diabetes in Greece

by
Styliani Ntavidi
1,
Panagiota Katsanou
1,
George Marakomichelakis
1,
Maria-Iosifina Kasdagli
2,
Eleni Antiochou
1,
Ioulia Mpali
1,
Anda-Monica Kakou
1,
Konstantinos Tsioufis
3,
George Dimitriadis
4 and
Vaia Lambadiari
4,*
1
Outpatient Clinic of Diabetic Foot, 4th Department of Internal Medicine, General Hospital of Evangelismos, 10676 Athens, Attiki, Greece
2
Department of Hygiene, Epidemiology and Medical Statistics, National and Kapodistrian University of Athens, 11527 Athens, Attiki, Greece
3
Department of Cardiology, General Hospital of Hipokration, 11527 Athens, Greece
4
2nd Department of Internal Medicine, Research Institute and Diabetes Center, National and Kapodistrian University of Athens Medical School, Attikon University Hospital, 12462 Haidari, Greece
*
Author to whom correspondence should be addressed.
Nutrients 2023, 15(1), 72; https://doi.org/10.3390/nu15010072
Submission received: 17 November 2022 / Revised: 11 December 2022 / Accepted: 15 December 2022 / Published: 23 December 2022
(This article belongs to the Special Issue Insulin 100th Anniversary: Century of Innovation for Diabetes)
Browse Figures
Versions Notes

Abstract

:
Diabetic peripheral neuropathy (DPN) is present in 20–50% of cases with diabetes. The pathophysiology of DPN is not yet clear regarding hypertension (HTN). The aim of this study was to assess the association between the stages of DPN and HTN in a Greek population with diabetes. We examined 102 adults for diabetic neuropathy (DPN) from November 2020 to December 2021, using the Toronto Clinical Neuropathy Scale System (TCNSS) to categorize them into two groups (no/mild DPN versus medium/severe DPN). Ambulatory blood pressure monitoring was performed to evaluate their hypertensive status. Univariate and multivariate logistic regression analyses were performed to assess the association between the stage of DPN and HTN. The multivariate analysis, considering sex, age, and dipping status, did not show statistically significant associations between stages of HTN and DPN. However, in contrast to dippers, non-dippers had an almost four-times higher risk of developing medium-to-severe DPN (odds ratio (OR) 3.93; 95% confidence interval (CI) [1.33–11.64]); females, in contrast to males, had a 65% lower risk of developing moderate/severe DPN (OR 0.35; 95%CI [0.14–0.92]). In conclusion, our findings showed no statistically significant associations between DPN and HTN; however, dipping status, hyperglycemia, and female sex were shown to play a role in the pathophysiology of DPN.

1. Introduction

Diabetic complications of the lower extremities are common [1]. Diabetic peripheral neuropathy (DPN) is the most common neuropathy in developed countries and worldwide [1,2]. According to the International Diabetes Federation (IDF), the prevalence of DPN is expected to rise from 40–60 million people in 2020 to 578 million by 2030 and to 700 million by 2045 [3]. Up to 50% of populations with diabetes may develop DPN during their lifetime [4,5,6], while it is estimated that subjects with type 2 diabetes (T2DM) have a two-fold higher risk compared to type 1 diabetes (T1DM) [7,8,9].
Diabetic complications of the lower extremities are also costly [10]. Diabetic foot, a combination of DPN and ulceration in 85% of cases, is the main reason behind non-traumatic amputations of the lower limbs [10]. It is estimated that every 30 s, one amputation happens in the diabetic population [10]. This leads to almost 24.4% of the Total Fund of Global Health being spent on complications of the limbs [11]. Furthermore, the psychological burden from neuropathic pain and impaired sensibility adds to the reduced quality of life, which may lead to depression [1].
Finally, the pathogenic mechanisms of diabetic complications, including foot complications, are also complex and are due to vascular damage. It is well known that the underlying drivers of the development of microvascular/macrovascular disease are insulin resistance and tissue exposure to chronic hyperglycemia and hyperlipidemia (glucotoxicity/ lipotoxicity) [12,13]. While DPN is often routinely considered a microvascular complication of diabetes, this concept does not fully address the complexities of direct neuronal involvement [1,14].
Identifying the risk factors of diabetic complications may enable health providers to set up better prevention strategies to alleviate the personal, social, and economic burden of society. Several studies have assessed the role of hypertension (HTN) in the development of DPN but with inconsistent results. Therefore, the aim of this study was to assess the association between the stage of DPN and HTN in a Greek diabetic population.

2. Materials and Methods

We conducted an observational study from November 2020 to December 2021 in Evangelismos General Hospital in Athens, Greece. We registered 102 patients with diabetes from the “Outpatient Clinic of Diabetic Foot” and the “Outpatient Clinic of Hypertension”. The study protocol was approved by the Scientific and Ethics Committee of Evangelismos General Hospital. The patients were informed in detail about the purpose of the study and signed a consent form.
A qualified and trained physician filled out a personal structured sheet for every participant, with detailed information on demographic characteristics and medical history, with an emphasis on the type and duration of diabetes (DM), hypertension (HTN) and dyslipidemia, medications (including hypoglycemic/antihypertensive/lipid-lowering agents), body mass index (BMI), smoking and alcohol use, and physical activity/exercise. In all participants, blood test analysis was conducted in the early morning hours (08:00–10:00 am) after an overnight fast for at least 10 h. The eGFR was calculated according to the MDRD equation.
Blood pressure (BP) was measured by the ambulatory blood pressure monitoring (ABPM) device from Micro life. The function of this device was explained in detail to each participant to obtain cooperation. With an appropriately sized BP cuff (medium, large, x-large) on the non-dominant upper limb and a frequency of measurements of every 20 min, the participants were encouraged to maintain their usual schedule and to record sleep hours during the day and night.
All participants underwent screening for peripheral neuropathologic symptoms, including numbness of the lower limbs, acupuncture-like sensation, fatigue, staggered walking, and upper limb symptoms. All assessments were performed by the same physician. The symptoms were graded according to the standard criteria for the evaluation of peripheral neuropathy (including acupuncture pain, touch sensation, temperature sensation, vibration sensation, positional sensation, bilateral knee reflex, and ankle reflex).
For the classification of hypertension (HTN), we followed the ESH/ESC guidelines (2018 ESC/ESH Clinical Practice Guidelines for the Management of Arterial Hypertension) [15]. More specifically, optimal BP was defined as systolic blood pressure (SBP) <120 mmHg and diastolic blood pressure (DBP) <80 mmHg, normal SBP as 120–129 mmHg and DBP 80–84 mmHg, high normal SBP as 130–139 mmHg and DBP 85–89 mmHg, grade 1 HTN as 140–159 mmHg/90–99 mmHg, and grade 2 HTN as 160–179 mmHg/100–109 mmHg. Dipping was estimated as an abnormal fall in mean SBP during sleep up to 10–20%. Dipping of less than 10% of the mean daytime SBP was considered non-dipping, whereas a rise in the nighttime mean SBP was considered reverse dipping.
Using the 2002 Toronto Clinical Neuropathy Scoring System (TCNSS), which includes a neurologic score, neurologic reflex score, and sensory function score, DPN was graded as follows: (1) 0–5 points, no evidence of DPN (non-DPN); (2) 6–8 points, mild DPN; (3) 9–11 points, moderate DPN; and (4) 12–19 points, severe DPN. Participants were divided into two subgroups, one with absent/mild DPN and the other with moderate/severe DPN.

Statistical Analysis

Participants’ data were summarized as the mean and standard deviation for the continuous variables and as frequencies and percentages for categorical variables. For continuous variables, differences between the two groups (those with absent/mild DPN versus those with moderate/severe DPN) were assessed via a two-sample t-test. For categorical variables, relevant differences were assessed by Pearson’s chi-square test. Initially, we performed univariate logistic regression models and afterward a multivariate logistic regression model to evaluate the association between the stage of DPN and that of HTN, using the backward stepwise approach. In the final logistic regression model, only the statistically significant variables were included (p <0.05), whereas age, sex, and stages of hypertension were included as potential confounders. Statistical analysis of the data was performed using Stata/SE 14.0.

3. Results

Most of our patients were male (64%), and the mean age was 60.45 ± 11.3 years. The mean 24 h SBP and DBP were 123.47± 11.92 mmHg and 71.23 ± 7.45 mmHg, respectively (Table 1). Most participants had T2DM (94.11%) and 44% were obese. Of the individuals with T2DM, 50 were on oral antidiabetic agents (49.02%), 18 were on insulin (17.65%), and 30 (29.41%) were on a combination of insulin and oral agents (Figure 1). The majority were receiving antihypertensive therapy (78.43%) and specifically receiving ACE inhibitors or ARBs (Figure 2). Forty patients were receiving no antihypertensive therapy and, independently of DPN status, 35% of them were found with unknown HTN (Figure 3). The 24 h mean SBP was 123.47 ± 11.92 mmHg. The 24 h mean DBP and nocturnal SBP were found to be statistically significantly associated with DPN status (p-value 0.0181 and 0.0371, respectively; Table 2, and 62.5% of the participants were either non-dippers or reverse dippers (Table 3). The two groups differed in HbA1c, 24 h DBP, nighttime SBP, nighttime DBP, and BMI (Table 1, Table 2 and Table 3). Smoking status and the number and type of antihypertensives and antidiabetics were not found to be statistically significant when associated with the stage of DPN or dipping status (data not shown).
To investigate the relationship between the stages of DPN and HTN, we performed univariate and multivariate logistic regression analyses (Table 4). The multivariate model included other possible independent confounders, such as age, sex, ABPM dipping, and 24 h hypertension stages, and showed that females had a lower risk of moderate or severe DPN (OR 0.35; 95%CI [0.14–0.92]) versus male participants (Table 4). Furthermore, non-dippers had a higher risk of moderate/severe DPN (versus dippers) (OR 3.93; 95%CI [1.33–11.64], Table 4), while age and 24 h-hypertension stage did not reach statistical significance in the multivariate model.

4. Discussion

In our study, we evaluated the relationship between the stages of DPN and HTN in a Greek population with diabetes (93% T2DΜ, 7% T1DΜ). Moderate/severe DPN was present in 89.6% and 10.4% of T2DΜ and T1DΜ participants, respectively. Our results also showed that, in contrast to men with T2DM, women have a lower risk of developing DPN. In agreement with other studies, such as by Rossboth et al. [16], this may be explained by the fact that the majority of men with T2DM lack adherence to antidiabetic therapy, resist lifestyle changes and the cessation of smoking, and are more vulnerable to minor trauma of the feet. On the contrary, Khan et al. [17] showed that the female gender is more susceptible to DPN progression. This heterogeneity in results may be due to racial and cultural differences.
Several studies have shown an association between HTN and DPN [18,19,20,21,22]. Cardoso et al. [23] and Gebabo et al. [24] reported that patients with resistant HTN had a 2.36-fold higher risk of developing DPN. Likewise, Huang et al. showed that normotensive individuals with diabetes and DPN had a higher normal SBP [25]. These studies suggest that the existence of DPN may be associated with a higher BP in normotensives and with a more difficult-to-control HTN in hypertensives.
Blood pressure is regulated by many factors and, therefore, its management becomes difficult when the severity of these factors increases despite the use of antihypertensives.
The risk factors of hypertension in general and particularly in patients with DM include, among others, older age, lifestyle (obesity, excessive salt intake, less physical activity/exercise, smoking, alcohol consumption, mental stress), hyperglycemia, and a longer duration of diabetes and certain comorbidities, such as dyslipidemia, chronic kidney disease, peripheral artery disease, obstructive sleep apnea syndrome, etc. [15,26,27,28,29]. Our results showed no statistically significant correlations between the stages of DPN (classified as the TCNSS in subjects) and HTN and, therefore, do not support an association. In agreement with our results, previous reports showed that the presence of HTN was not associated with the progression of DPN. More specifically, the Study of Maastricht [30] and the systematic review of Ross both et al. [31] did not provide evidence for an association between the components of metabolic syndrome and especially HTN and DPN. Baxi et al. also showed no statistically significant association between HTN and DPN [32]. According to the recent review by Lee et al., there is no indication that the monitoring of HTN prevents the development of DPN [33].
The pathogenesis of diabetic neuropathy is complex and involves many factors. Although persistent chronic hyperglycemia has been considered the main cause of microvascular complications, including neuropathy, studies have shown that genetic polymorphisms, hypoinsulinemia or insulin resistance, and hyperinsulinemia may also play a major role [34,35,36].
Hyperglycemia is the main metabolic characteristic of both T2DM and T1DM, and is related to direct axonal damage and demyelination, early metabolic abnormalities of the nerves, an increase in polyol pathway activity resulting in the accumulation of sorbitol and fructose and a decrease in Na+/K+-ATPase activity, mitochondrial dysregulation, and the activation of inflammation [37,38,39]. Indeed, the best-known treatment for the prevention of neuropathic complications is strict glycemic control. In our population, HbA1c, which represents the mean level of glycemia in the last 2–3 months, was >7% in 52.48% of the participants, and 61.7% of them suffered from moderate to severe DPN (p-value 0.08). These results suggest that hyperglycemia played a major role in the development of DPN in our study group.
In addition to hyperglycemia, loss of insulin signaling due to insulin resistance or insulinopenia may also contribute to the development of DPN [13,40]. It is established that there are insulin receptors on the neurons of the peripheral nervous system (PNS) [40,41,42]. Plasma insulin levels within a normal range promote neuronal outgrowth and survival and maintain sensory function by regulating the synthesis of key neuromodulator proteins and peptides [42,43]. Therefore, a decrease in insulin action may have direct effects on neuronal function and metabolism and contribute independently to the development of DPN [43,44].
Insulin resistance, a hallmark of T2DM and obesity, is a clinical condition characterized by the impaired responsiveness of insulin-sensitive tissues to insulin and a compensatory increase in insulin release by β-cells [45]. In healthy subjects or in patients with T2DM/obesity, the development of insulin resistance has been linked to an increased risk for macro- and microvascular complications, independently of hyperglycemia, dyslipidemia, or other cardiovascular risk factors [46,47]. In subjects with impaired glucose tolerance or overt T2DM, Thrainsdottir et al. [48] investigated the association between glucose intolerance and DPN by performing oral glucose tolerance tests and nerve biopsies. In these subjects, DPN was present in 44% and 60% of the individuals with impaired glucose tolerance orT2DM, respectively. Peripheral nerve biopsies showed increased thickening of the endo neural capillary basement membrane and a decreased luminal area during the progression from impaired glucose tolerance to overt T2DM. The authors [49] concluded that capillary microangiopathy and neural hypoperfusion are early mechanisms in the process underlying DPN in T2DM and are due to the presence of insulin resistance. Insulin resistance is also present in T1DM, due, at least in part, to the presence of obesity, chronic hyperglycemia, and the exogenous administration of insulin [49]. In T1DM, insulin resistance at baseline has been reported to be associated with an increased subsequent risk for both macro- and microvascular complications including neuropathy [50].
Insulin resistance is associated with hyperinsulinemia, which has growth-promoting effects; increases the risk for hypoglycemia and high glucose variability, endothelial damage, and proinflammatory and prothrombotic abnormalities; causes hypertension and weight gain, and can also induce or aggravate insulin resistance [51,52]. In T2DM, hyperinsulinemia is present before clinical diagnosis, and during disease progression from prediabetes to overt T2DM [53]. In T2DM, there is a link between reduced insulin signaling and peripheral nervous system (PNS) insulin resistance, resulting in damaged neurite outgrowth [54]. The development of neuronal insulin resistance by insulin administration is supported by studies reporting reduced downstream insulin signaling in vivo in the PNS of insulin-resistant ob/ob mice in response to either IT or IP) injections of insulin [44]. In our study, 18 patients (17.65%) were on insulin treatment alone and 30 patients (29.41%) were on a combination of insulin and oral agents. Of these subjects, 14.58% on insulin alone and 37.5% on a combination of insulin and oral agents had developed moderate/severe DPN. However, this association was not statistically significant (p =0.191), suggesting that, in our population, hyperinsulinemia was not associated with DPN development.
In addition to hyperinsulinemia, an association of hypoinsulinemiawith DPN has also been described. In T2DM, the deterioration of insulin secretion and hypoinsulinemia may develop during the progression of the disease due to treatment failure with diet or oral hypoglycemic agents and poor glycemic control [53]. In adults with obesity and T2DM, Partanen et al. [55] investigated the occurrence and risk factors of DPN at five years after the diagnosis of T2DM(mean HbA1c 9.3%), when all subjects were treated with nutritional interventions alone, and after ten years of follow-up (mean HbA1c 9%) when treatment involved a combination of oral hypoglycemic agents and insulin. The results showed that DPN was present at five years of overt diabetes, and its frequency/severity was increased at 10 years, suggesting a cumulative effect of neuropathic factors over time. Postprandial plasma insulin and C-peptide levels at five and ten years were lower than in age/weight-matched controls; furthermore, subjects with DPN had plasma insulin values lower than those without DPN. The authors concluded that hyperglycemia and hypoinsulinemia are strong predictors of both the frequency and severity of DPN in T2DM. In T1DM, hypoinsulinemia is present before clinical diagnosis due to progressive autoimmune β-cell destruction [40,42,56].
Our study showed a statistically significant association between dipping status and DPN, with non-dippers having an almost four times higher risk for moderate/severe DPN than dippers (OR 3.93; 95%CI [1.33–11.64]). This association was independent of HTN and glycemic control. In agreement with our results, Najafi et al. also showed that only dipping status, among all the parameters of ABPM, was a statistically significant risk factor for DPN progression [57].
Non-dipping is one of the most frequent patterns of individuals with diabetes and hypertension [58], and it has been demonstrated that these patients tend to have a higher nocturnal BP [59]. To some extent, non-dipping status is etiologically linked to the underlying cardiovascular autonomic neuropathy in this condition and to the sympathetic nervous system, which paradoxically prevails over the parasympathetic nervous system in these patients during the night [60].
According to Spallone et al. [61,62], the central role in the development of non-dipping/reverse dipping is played by the autonomic dysfunction present in prediabetes and overt T2DM and is characterized by sympathetic overactivity, sympathovagal unbalance, and loss of the circadian autonomic rhythm with sympathetic predominance during the night. Insulin resistance in type 2 diabetes can induce chemoreflex upregulation and baroreflex impairment, thus enhancing sympathetic overactivity. Additional factors are added to the pathogenesis of non-dipping while the disease progresses.
In diabetic autonomic neuropathy, abnormal circadian patterns of blood pressure and sympathovagal balance, with a reduced fall in blood pressure and the prevalence of sympathetic activity during the night, have been described. Orthostatic hypotension and supine hypertension in the advanced stages of autonomic diabetic neuropathy exert a contributory role. Other documented possible contributory factors are fluid redistribution from the extra- to the intravascular compartment in protein uric nephropathy, a compensatory nocturnal-pressure natriuresis in salt-sensitive hypertension in T2DM, and kidney failure, sleep disturbances, and neuropathic pain. According to Mahabala et al., the persistence of daytime BP into the night and the development of a non-dipper status seems to be secondary to the necessity for extended pressure natriuresis [63]. It is reported that, compared with the correlation between daytime sodium excretion and daytime BP, the correlation between nighttime sodium excretion and nocturnal BP is stronger [64]. All these factors act synergistically to disrupt circadian BP patterns and lead to a non-dipping pattern [61].
Non-dipping status or nocturnal hypertension was associated with target organ damage and an increased risk for cardiovascular disease (CVD) [65,66,67,68]. According to Spallone et al. [61], the finding of an abnormal circadian profile in patients with autonomic failure and a decreased vagal tone with simultaneous sympathetic predominance has been postulated as an independent factor of mortality after myocardial infarction. Moreover, nocturnal BP levels may be relevant to target organ damage, since hypertensive patients classified as non-dippers have a significantly higher frequency of stroke or greater left ventricular hypertrophy [62].
Dippers and non-dippers are different in their cardiovascular risk profiles, the severity of the disease, end-organ involvement, and long-term cardiovascular complications.
In our study, the population with diagnosed HTN was treated with one agent or a combination of antihypertensive agents, and the type of antihypertensive therapy did not show any statistically significant association with the stage of DPN. Furthermore, the status of dipping was not previously known, so every patient was on the conventional one-morning-dose treatment. Even though non-dipping has an increased risk for a worse overall prognosis [61,65,69], and the incidence of cardiovascular events is even worse in reverse dippers [70], the 2018 ESC/ESH guidelines do not provide recommendations on when-to-treat [15].
Six main classes of antihypertensive drugs (ACEIs, CCBs, β-blockers, diuretics, ARBs, and α-blockers) have been used worldwide. These drugs are traditionally administered once every morning, based on the results of many clinical trials showing the advantages of morning dosing in reducing the risk of cardiovascular diseases. On the other hand, chronotherapy is defined as a type of purposeful treatment that enhances the effectiveness and tolerance of a drug by choosing the optimal dosing time [71]. In the Heart Outcomes Prevention Evaluation (HOPE) study in 2000, ramipril administered at night demonstrated a decreased CVD risk by controlling nighttime BP; however, there was no direct comparison with daytime dosing in this study [72].Ten years later, the MAPEC study compared morning versus night doses of antihypertensive therapy and concluded that the nighttime dose achieved better overall BP control after a mean follow-up of 5.6 years in 2156 individuals [73]. More recently, the Hygia Chronotherapy Trial has demonstrated that a bedtime hypertension treatment strategy is safe and that the risk for adverse effects is comparable to the more common morning-time treatment strategy [74]. Moreover, in the meta-analysis by Xie et al, a prominent role of evening CCB in lowering blood pressure was reported [75].
Therefore, it may be reasonable to suggest the evening administration of an antihypertensive regimen to treat non-dippers. Furthermore, our study showed that, independently of the DPN stage, the percentage of undiagnosed HTN in patients with DM was 35%.HTN is mainly a silent disease and has a growing prevalence as the population ages. Therefore, undiagnosed HTN can be detected early only when public health systems adapt to national prevention programs. It has been shown that patients with undiagnosed HTN constitute more than 50% of the general population [76,77].Considering that our study population suffered also from DM and was therefore under monitoring and medical treatment for DM and DPN, it was expected that comorbidities, such as HTN, could be detected and controlled to limit the cardiovascular risk of these patients. This assumption could explain why the percentage of undiagnosed HTN was smaller in our patients than in the general population.
Alternatively, the fact that DPN can induce HTN through several mechanisms may also contribute to this 35% of undiagnosed HTN. Mechanisms such as the acceleration of subclinical atherosclerosis and reduction of arterial compliance [78], exacerbation of chronic inflammation, and oxidative stress and abnormal activation of the renin–angiotensin–aldosterone system have been proposed to contribute to the development of HTN in patients with DPN [79]. Another possible mechanism could be that DPN is accompanied by neurologic and parasympathetic/sympathetic damage, which contributes to the increase in BP [50]. Additional mechanisms of DPN-mediated HTN include higher levels of glycosylated end-products, which can also inhibit the release of vasorelaxants, such as nitric oxide and prostacyclin, triggering the release of endothelin and thromboxane A2, and hence lead to vasoconstriction, a decrease in tissue blood flow rates, hypoxia, and metabolic dysregulation [25,80].
Strengths of our study include the well-standardized data collection and the relatively homogenous nature of the study population, residing in distinct geographical locations, including rural and urban areas of Athens, as well as migrant populations. The findings of our study are limited by the small sample size and by the fact that ABPM was performed once. However, the comparison between groups showed clear differences in the statistical analysis. In addition, in our patient groups, there were more normotensive than hypertensive patients. Furthermore, the cross-sectional study design restricts causality inferences, warranting the cautious interpretation of the results.

5. Conclusions

In conclusion, our findings do not support an association between DPN and HTN. However, dipping status and female sex were shown to play a role in the pathophysiology of DPN. As 35% of patients with diabetes had undiagnosed HTN and dipping status is a risk factor for DPN, we suggest the use of ABPM both for the diagnosis of HTN and as a tool for the prognosis of DPN development. Early control of HTN with lifestyle changes and antihypertensive medications could contribute to delaying the progression of micro- and macroangiopathy, and therefore protect patients from DPN and improve their quality of life. Therefore, using ABPM once every 6–12 months seems to be a reasonable screening strategy. A better understanding of the mechanism of DPN may contribute to identifying the risk factors involved and enable health providers to set up better prevention programs. However, as our study was a cross-sectional study design, more studies using longitudinal data should be conducted to confirm our results.

Author Contributions

Conceptualization, S.N., P.K. and G.M.; Methodology and investigation, S.N., P.K., E.A. and I.M.; Software, validation S.N. and M.-I.K.; formal analysis, M.-I.K.; resources, P.K., G.M. and A.-M.K.; data curation, P.K.; writing—original draft preparation, S.N. and G.D.; writing—review and editing, V.L. and K.T.; supervision, V.L. All authors have read and agreed to the published version of the manuscript.

Funding

This research received no external funding.

Institutional Review Board Statement

The study was conducted in accordance with the Declaration of Helsinki and approved by the Institutional Review Board of EVANGELISMOS GENERAL HOSPITAL (protocol code 474,7-10-2021, Athens).

Informed Consent Statement

Informed consent was obtained from all subjects involved in the study.

Data Availability Statement

No applicable.

Acknowledgments

The authors are very grateful to the advisory board members for their valuable support in shaping the methods. They gratefully acknowledge George Marakomichelakis and Panagiota Katsanou from Evangelismos General Hospital for their valuable support and trust. They also gratefully acknowledge the help received from their teachers, George Dimitriadis and VaiaLambadiari.

Conflicts of Interest

The authors declare no conflict of interest.

Abbreviations

HTN: hypertension; DPN, diabetic peripheral neuropathy; TCNSS, Toronto Clinical Neuropathy Scale System; CCBs: calcium-channel blockers.

References

  1. Hicks, C.W.; Selvin, E. Epidemiology of Peripheral Neuropathy and Lower Extremity Disease in Diabetes. Curr. Diabetes Rep. 2019, 19, 86. [Google Scholar] [CrossRef]
  2. Venguidesvarane, A.G.; Jasmine, A.; Varadarajan, S.; Shriraam, V.; Muthuthandavan, A.R.; Durai, V.; Thiruvengadam, G.; Mahadevan, S. Prevalence of Vascular Complications Among Type 2 Diabetic Patients in a Rural Health Center in South India. J. Prim. Care Community Health 2020, 11, 2150132720959962. [Google Scholar] [CrossRef]
  3. Wang, M.; Zhang, Z.; Mi, J.; Wang, G.; Tian, L.; Zhao, Y.; Li, X.; Li, X.; Wang, X. Interventional Clinical Trials on Diabetic Peripheral Neuropathy: A Retrospective Analysis. J. Pain Res. 2021, 14, 2651–2664. [Google Scholar] [CrossRef]
  4. Dyck, P.J.; Kratz, K.M.; Karnes, J.L.; Litchy, W.J.; Klein, R.; Pach, J.M.; Wilson, D.M.; O’Brien, P.C.; Melton, L.J. The prevalence by staged severity of various types of diabetic neuropathy, retinopathy, and nephropathy in a population-based cohort: The Rochester Diabetic Neuropathy Study. Neurology 1993, 43, 817–824. [Google Scholar] [CrossRef] [PubMed]
  5. Darling, J.D.; McCallum, J.C.; Soden, P.A.; Meng, Y.; Wyers, M.C.; Hamdan, A.D.; Verhagen, H.J.; Schermerhorn, M.L. Predictive ability of the Society for Vascular Surgery Wound, Ischemia, and foot Infection (WIfI) classification system following infrapopliteal endovascular interventions for critical limb ischemia. J. Vasc. Surg. 2016, 64, 616–622. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  6. Tommerdahl, K.L.; Shapiro, A.L.B.; Nehus, E.J.; Bjornstad, P. Early microvascular complications in type 1 and type 2 diabetes: Recent developments and updates. Pediatr. Nephrol. 2021, 37, 79–93. [Google Scholar] [CrossRef] [PubMed]
  7. Iqbal, Z.; Azmi, S.; Yadav, R.; Ferdousi, M.; Kumar, M.; Cuthbertson, D.J.; Lim, J.; Malik, R.A.; Alam, U. Diabetic Peripheral Neuropathy: Epidemiology, Diagnosis, and Pharmacotherapy. Clin. Ther. 2018, 40, 828–849. [Google Scholar] [CrossRef] [Green Version]
  8. Martin, C.L.; Albers, J.W.; Pop-Busui, R. Neuropathy and related findings in the diabetes control and complications trial/epidemiology of diabetes interventions and complications study. Diabetes Care 2014, 37, 31–38. [Google Scholar] [CrossRef] [Green Version]
  9. Pop-Busui, R.; Boulton, A.J.; Feldman, E.L.; Bril, V.; Freeman, R.; Malik, R.A.; Sosenko, J.M.; Ziegler, D. Diabetic Neuropathy: A Position Statement by the American Diabetes Association. Diabetes Care 2017, 40, 136–154. [Google Scholar] [CrossRef] [Green Version]
  10. Boulton, A.J.M. The diabetic foot: Grand overview, epidemiology and pathogenesis. Diabetes/Metab. Res. Rev. 2008, 24, S3–S6. [Google Scholar] [CrossRef]
  11. Al-Rubeaan, K.; Al Derwish, M.; Ouizi, S.; Youssef, A.M.; Subhani, S.N.; Ibrahim, H.M.; Alamri, B.N. Diabetic Foot Complications and Their Risk Factors from a Large Retrospective Cohort Study. PLoS ONE 2015, 10, e0124446. [Google Scholar] [CrossRef] [PubMed]
  12. Vithian, K.; Hurel, S. Microvascular complications: Pathophysiology and management. Clin. Med. 2010, 10, 505–509. [Google Scholar] [CrossRef] [PubMed]
  13. Diabetes Control and Complications Trial Research Group; Nathan, D.M.; Genuth, S.; Lachin, J.; Cleary, P.; Crofford, O.; Davis, M.; Rand, L.; Siebert, C. The Effect of Intensive Treatment of Diabetes on the Development and Progression of Long-Term Complications in Insulin-Dependent Diabetes Mellitus. N. Engl. J. Med. 1993, 329, 977–986. [Google Scholar] [CrossRef]
  14. Zochodne, D.W. Diabetes and the plasticity of sensory neurons. Neurosci. Lett. 2015, 596, 60–65. [Google Scholar] [CrossRef]
  15. Williams, B.; Mancia, G.; Spiering, W.; AgabitiRosei, E.; Azizi, M.; Burnier, M.; Clement, D.L.; Coca, A.; de Simone, G.; Dominiczak, A.; et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology (ESC) and the European Society of Hypertension (ESH). Eur. Heart J. 2018, 39, 3021–3104. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  16. Rossboth, S.; Rossboth, B.; Schoenherr, H.; Lechleitner, M.; Oberaigner, W. Risk factors for diabetic foot complications among patients with type 2 diabetes in Austria–A registry-based retrospective cohort study. Endocrinol. Diabetes Metab. 2021, 4, e00286. [Google Scholar] [CrossRef]
  17. Khan, M.I.H.; Azhar, U.; Zubair, F.; Khan, Z.A. Can we link foot ulcer with risk factors in diabetics? A study in a tertiary care hospital. Pak. J. Med Sci. 2018, 34, 1375–1380. [Google Scholar] [CrossRef]
  18. Seid, M.A.; Akalu, Y.; Gela, Y.Y.; Belsti, Y.; Diress, M.; Fekadu, S.A.; Dagnew, B.; Getnet, M. Microvascular complications and its predictors among type 2 diabetes mellitus patients at Dessie town hospitals, Ethiopia. Diabetol. Metab. Syndr. 2021, 13, 86. [Google Scholar] [CrossRef]
  19. Stegenga, M.E.; van der Crabben, S.N.; Levi, M.; de Vos, A.F.; Tanck, M.W.; Sauerwein, H.P.; van der Poll, T. Hyperglycemia Stimulates Coagulation, Whereas Hyperinsulinemia Impairs Fibrinolysis in Healthy Humans. Diabetes 2006, 55, 1807–1812. [Google Scholar] [CrossRef] [Green Version]
  20. Stout, R.W. Insulin-stimulated lipogenesis in arterial tissue in relation to diabetes and atheroma. Lancet 1968, 292, 702–703. [Google Scholar] [CrossRef]
  21. Dandona, P.; Chaudhuri, A.; Dhindsa, S. Proinflammatory and Prothrombotic Effects of Hypoglycemia. Diabetes Care 2010, 33, 1686–1687. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  22. Azhar, A.; Basheer, M.; Abdelgawad, M.S.; Roshdi, H.; Kamel, M.F. Prevalence of Peripheral Arterial Disease in Diabetic Foot Ulcer Patients and its Impact in Limb Salvage. Int. J. Low. Extrem. Wounds 2021, 15347346211027063. [Google Scholar] [CrossRef] [PubMed]
  23. Cardoso, C.R.L.; Leite, N.C.; Bacan, G.; Ataíde, D.S.; Gorgonio, L.K.; Salles, G.F. Prognostic Importance of Resistant Hypertension in Patients With Type 2 Diabetes: The Rio de Janeiro Type 2 Diabetes Cohort Study. Diabetes Care 2020, 43, 219–227. [Google Scholar] [CrossRef] [PubMed]
  24. Gebabo, T.F.; Zewdie, T.H.; Shagaro, S.S.; Haile, F. Determinants of peripheral neuropathy among diabetic patients under follow-up in chronic care clinics of public hospitals at Gamo and Gofa zones, southern Ethiopia. PLoS ONE 2021, 16, e0246722. [Google Scholar] [CrossRef]
  25. Huang, L.; Zhang, Y.; Wang, Y.; Shen, X.; Yan, S. Diabetic Peripheral Neuropathy Is Associated With Higher Systolic Blood Pressure in Adults With Type 2 Diabetes With and Without Hypertension in the Chinese Han Population. Can. J. Diabetes 2020, 44, 615–623. [Google Scholar] [CrossRef]
  26. Abougalambou, S.S.I.; Abougalambou, A.S. A study evaluating prevalence of hypertension and risk factors affecting on blood pressure control among type 2 diabetes patients attending teaching hospital in Malaysia. Diabetes Metab. Syndr. Clin. Res. Rev. 2013, 7, 83–86. [Google Scholar] [CrossRef]
  27. Devi, P.; Rao, M.; A Sigamani, A.; A Faruqui, A.; Jose, M.; Gupta, R.; Kerkar, P.; Jain, R.K.; Joshi, R.; Chidambaram, N.; et al. Prevalence, risk factors and awareness of hypertension in India: A systematic review. J. Hum. Hypertens. 2013, 27, 281–287. [Google Scholar] [CrossRef] [Green Version]
  28. Benenson, I.; Waldron, F.A.; Jadotte, Y.T.; Dreker, M.P.; Holly, C. Risk factors for hypertensive crisis in adult patients: A systematic review. JBI Èvid. Synth. 2021, 19, 1292–1327. [Google Scholar] [CrossRef]
  29. Naing, C.; Aung, K. Prevalence and risk factors of hypertension in myanmar: A systematic review and meta-analysis. Medicine 2014, 93, e100. [Google Scholar] [CrossRef]
  30. Van Der Velde, J.H.P.M.; Koster, A.; Strotmeyer, E.S.; Mess, W.H.; Hilkman, D.; Reulen, J.P.H.; Stehouwer, C.D.A.; Henry, R.M.A.; Schram, M.T.; Van Der Kallen, C.J.H.; et al. Cardiometabolic risk factors as determinants of peripheral nerve function: The Maastricht Study. Diabetologia 2020, 63, 1648–1658. [Google Scholar] [CrossRef]
  31. Rossboth, S.; Lechleitner, M.; Oberaigner, W. Risk factors for diabetic foot complications in type 2 diabetes—A systematic review. Endocrinol. Diabetes Metab. 2021, 4, e00175. [Google Scholar] [CrossRef] [PubMed]
  32. Baxi, H.; Habib, A.; Hussain, S.; Hussain, S.; Dubey, K. Prevalence of peripheral neuropathy and associated pain in patients with diabetes mellitus: Evidence from a cross-sectional study. J. Diabetes Metab. Disord. 2020, 19, 1011–1017. [Google Scholar] [CrossRef] [PubMed]
  33. Lee, K.A.; Park, T.S.; Jin, H.Y. Non-glucose risk factors in the pathogenesis of diabetic peripheral neuropathy. Endocrine 2020, 70, 465–478. [Google Scholar] [CrossRef]
  34. Vinik, A.I.; Erbas, T.; Stansberry, K.B.; Pittenger, G.L. Small fiber neuropathy and neurovascular disturbances in diabetes mellitus. Exp. Clin. Endocrinol. Diabetes 2001, 109 (Suppl. 2), S451–S473. [Google Scholar] [CrossRef]
  35. Han, L.; Ji, L.; Chang, J.; Wen, J.; Zhao, W.; Shi, H.; Zhou, L.; Li, Y.; Hu, R.; Hu, J.; et al. Peripheral neuropathy is associated with insulin resistance independent of metabolic syndrome. Diabetol. Metab. Syndr. 2015, 7, 14. [Google Scholar] [CrossRef] [Green Version]
  36. Lee, K.O.; Nam, J.S.; Ahn, C.W.; Hong, J.; Kim, S.M.; Sunwoo, I.-N.; Moon, J.-S.; Na, S.-J.; Choi, Y.-C. Insulin resistance is independently associated with peripheral and autonomic neuropathy in Korean type 2 diabetic patients. Acta Diabetol. 2012, 49, 97–103. [Google Scholar] [CrossRef]
  37. Feldman, E.L.; Nave, K.-A.; Jensen, T.S.; Bennett, D.L.H. New Horizons in Diabetic Neuropathy: Mechanisms, Bioenergetics, and Pain. Neuron 2017, 93, 1296–1313. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  38. Vincent, A.M.; Callaghan, B.C.; Smith, A.L.; Feldman, E. Diabetic neuropathy: Cellular mechanisms as therapeutic targets. Nat. Rev. Neurol. 2011, 7, 573–583. [Google Scholar] [CrossRef]
  39. Edwards, J.L.; Vincent, A.M.; Cheng, H.T.; Feldman, E.L. Diabetic neuropathy: Mechanisms to management. Pharmacol. Ther. 2008, 120, 1–34. [Google Scholar] [CrossRef] [Green Version]
  40. Sugimoto, K.; Baba, M.; Suzuki, S.; Yagihashi, S. The Impact of Low-Dose Insulin on Peripheral Nerve Insulin Receptor Signaling in Streptozotocin-Induced Diabetic Rats. PLoS ONE 2013, 8, e74247. [Google Scholar] [CrossRef]
  41. Plum, L.; Schubert, M.; Brüning, J.C. The role of insulin receptor signaling in the brain. Trends Endocrinol. Metab. 2005, 16, 59–65. [Google Scholar] [CrossRef] [PubMed]
  42. Baiou, D.; Santha, P.; Avelino, A.; Charrua, A.; Bacskai, T.; Matesz, K.; Cruz, F.; Nagy, I. Neurochemical characterization of insulin receptor-expressing primary sensory neurons in wild-type and vanilloid type 1 transient receptor potential receptor knockout mice. J. Comp. Neurol. 2007, 503, 334–347. [Google Scholar] [CrossRef] [PubMed]
  43. Murakawa, Y.; Zhang, W.; Pierson, C.R.; Brismar, T.; Östenson, C.-G.; Efendic, S.; Sima, A.A.F. Impaired glucose tolerance and insulinopenia in the GK-rat causes peripheral neuropathy. Diabetes/Metabolism Res. Rev. 2002, 18, 473–483. [Google Scholar] [CrossRef]
  44. Grote, C.W.; Wright, D.E. A Role for Insulin in Diabetic Neuropathy. Front. Neurosci. 2016, 10, 581. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  45. Roden, M.; Shulman, G.I. The integrative biology of type 2 diabetes. Nature 2019, 576, 51–60. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  46. Laakso, M.; Kuusisto, J. Insulin resistance and hyperglycaemia in cardiovascular disease development. Nat. Rev. Endocrinol. 2014, 10, 293–302. [Google Scholar] [CrossRef]
  47. Groop, P.-H.; Forsblom, C.; Thomas, M.C. Mechanisms of Disease: Pathway-selective insulin resistance and microvascular complications of diabetes. Nat. Clin. Pract. Endocrinol. Metab. 2005, 1, 100–110. [Google Scholar] [CrossRef]
  48. Thrainsdottir, S.; Malik, R.A.; Dahlin, L.B.; Wiksell, P.; Eriksson, K.F.; Rosén, I.; Petersson, J.; Greene, D.A.; Sundkvist, G. Endoneurial Capillary Abnormalities Presage Deterioration of Glucose Tolerance and Accompany Peripheral Neuropathy in Man. Diabetes 2003, 52, 2615–2622. [Google Scholar] [CrossRef] [Green Version]
  49. Corbin, K.D.; Driscoll, K.A.; Pratley, R.E.; Smith, S.R.; Maahs, D.M.; Mayer-Davis, E.J. Obesity in Type 1 Diabetes: Pathophysiology, Clinical Impact, and Mechanisms. Endocr. Rev. 2018, 39, 629–663. [Google Scholar] [CrossRef] [Green Version]
  50. Kilpatrick, E.S.; Rigby, A.S.; Atkin, S.L. Insulin resistance, the metabolic syndrome, and complication risk in type 1 diabetes: “double diabetes” in the Diabetes Control and Complications Trial. Diabetes Care 2007, 30, 707–712. [Google Scholar] [CrossRef]
  51. Ferrannini, E.; Galvan, A.Q.; Gastaldelli, A.; Camastra, S.; Sironi, A.M.; Toschi, E.; Baldi, S.; Frascerra, S.; Monzani, F.; Antonelli, A.; et al. Insulin: New roles for an ancient hormone. Eur. J. Clin. Investig. 1999, 29, 842–852. [Google Scholar] [CrossRef] [PubMed]
  52. King, G.L.; Goodman, A.D.; Buzney, S.; Moses, A.; Kahn, C.R. Receptors and growth-promoting effects of insulin and insulinlike growth factors on cells from bovine retinal capillaries and aorta. J. Clin. Investig. 1985, 75, 1028–1036. [Google Scholar] [CrossRef] [PubMed]
  53. Niskanen, L.K.; I Uusitupa, M.; Sarlund, H.; Siitonen, O.; Pyörälä, K. Five-Year Follow-Up Study on Plasma Insulin Levels in Newly Diagnosed NIDDM Patients and Nondiabetic Subjects. Diabetes Care 1990, 13, 41–48. [Google Scholar] [CrossRef]
  54. Singh, B.; Xu, Y.; McLaughlin, T.; Singh, V.; Martinez, J.A.; Krishnan, A.; Zochodne, D.W. Resistance to trophic neurite outgrowth of sensory neurons exposed to insulin. J. Neurochem. 2012, 121, 263–276. [Google Scholar] [CrossRef] [PubMed]
  55. Partanen, J.; Niskanen, L.; Lehtinen, J.; Mervaala, E.; Siitonen, O.; Uusitupa, M. Natural History of Peripheral Neuropathy in Patients with Non-Insulin-Dependent Diabetes Mellitus. N. Engl. J. Med. 1995, 333, 89–94. [Google Scholar] [CrossRef] [PubMed]
  56. Brussee, V.; Cunningham, F.A.; Zochodne, D.W. Direct Insulin Signaling of Neurons Reverses Diabetic Neuropathy. Diabetes 2004, 53, 1824–1830. [Google Scholar] [CrossRef] [Green Version]
  57. Najafi, M.T.; Khaloo, P.; Alemi, H.; Jaafarinia, A.; Blaha, M.J.; Mirbolouk, M.; Mansournia, M.A.; Afarideh, M.; Esteghamati, S.; Nakhjavani, M.; et al. Ambulatory blood pressure monitoring and diabetes complications. Medicine 2018, 97, e12185. [Google Scholar] [CrossRef]
  58. Kario, K. Prognosis in Relation to Blood Pressure Variability. Hypertension 2015, 65, 1163–1169. [Google Scholar] [CrossRef] [Green Version]
  59. Epstein, M.; Sowers, J.R. Diabetes mellitus and hypertension. Hypertension 1992, 19, 403–418. [Google Scholar] [CrossRef] [Green Version]
  60. Kim, Y.-S.; Davis, S.C.A.T.; Stok, W.J.; van Ittersum, F.J.; van Lieshout, J.J. Impaired nocturnal blood pressure dipping in patients with type 2 diabetes mellitus. Hypertens. Res. 2019, 42, 59–66. [Google Scholar] [CrossRef]
  61. Spallone, V. Blood Pressure Variability and Autonomic Dysfunction. Curr. Diabetes Rep. 2018, 18, 137. [Google Scholar] [CrossRef] [PubMed]
  62. Spallone, V.; Bernardi, L.; Ricordi, L.; Soldà, P.; Maiello, M.R.; Calciati, A.; Gambardella, S.; Fratino, P.; Menzinger, G. Relationship Between the Circadian Rhythms of Blood Pressure and Sympathovagal Balance in Diabetic Autonomic Neuropathy. Diabetes 1993, 42, 1745–1752. [Google Scholar] [CrossRef] [PubMed]
  63. Mahabala, C.; Kamath, P.; Bhaskaran, U.; Pai, N.D.; Pai, A.U. Antihypertensive therapy: Nocturnal dippers and nondippers. Do we treat them differently? Vasc. Health Risk Manag. 2013, 9, 125–133. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  64. Wang, C.; Ye, Y.; Liu, C.; Zhou, Y.; Lv, L.; Cheng, C.; Li, S.; Lou, T.; Liu, X. Evening versus morning dosing regimen drug therapy for chronic kidney disease patients with hypertension in blood pressure patterns: A systematic review and meta-analysis. Intern. Med. J. 2017, 47, 900–906. [Google Scholar] [CrossRef] [PubMed]
  65. Liu, X.; Liu, X.; Huang, W.; Leo, S.; Li, Y.; Liu, M.; Yuan, H. Evening -Versus Morning- Dosing Drug Therapy for Chronic Kidney Disease Patients with Hypertension: A Systematic Review. Kidney Blood Press. Res. 2014, 39, 427–440. [Google Scholar] [CrossRef]
  66. Salles, G.F.; Reboldi, G.; Fagard, R.H.; Cardoso, C.R.; Pierdomenico, S.D.; Verdecchia, P.; Eguchi, K.; Kario, K.; Hoshide, S.; Polonia, J.; et al. Prognostic Effect of the Nocturnal Blood Pressure Fall in Hypertensive Patients: The Ambulatory Blood Pressure Collaboration in Patients With Hypertension (ABC-H) Meta-Analysis. Hypertension 2016, 67, 693–700. [Google Scholar] [CrossRef]
  67. Vij, R.; Peixoto, A.J. Management of nocturnal hypertension. Expert Rev. Cardiovasc. Ther. 2009, 7, 607–618. [Google Scholar] [CrossRef]
  68. Hermida, R.C.; Ayala, D.E.; Fernández, J.R.; Mojón, A.; Smolensky, M.H. Hypertension: New perspective on its definition and clinical management by bedtime therapy substantially reduces cardiovascular disease risk. Eur. J. Clin. Investig. 2018, 48, e12909. [Google Scholar] [CrossRef] [Green Version]
  69. Schillaci, G.; Battista, F.; Settimi, L.; Schillaci, L.; Pucci, G. Antihypertensive Drug Treatment and Circadian Blood Pressure Rhythm: A Review of the Role of Chronotherapy in Hypertension. Curr. Pharm. Des. 2015, 21, 756–772. [Google Scholar] [CrossRef]
  70. Fagard, R.H.; Thijs, L.; A Staessen, J.; Clement, D.L.; De Buyzere, M.L.; A De Bacquer, D. Night–day blood pressure ratio and dipping pattern as predictors of death and cardiovascular events in hypertension. J. Hum. Hypertens. 2009, 23, 645–653. [Google Scholar] [CrossRef]
  71. Hermida, R.C.; Hermida-Ayala, R.G.; Smolensky, M.H.; Mojón, A.; Crespo, J.J.; Otero, A.; Ríos, M.T.; Domínguez-Sardiña, M.; Fernández, J.R. Does Timing of Antihypertensive Medication Dosing Matter? Curr. Cardiol. Rep. 2020, 22, 118. [Google Scholar] [CrossRef] [PubMed]
  72. Gerstein, H.C. Reduction of cardiovascular events and microvascular complications in diabetes with ACE inhibitor treatment: HOPE and MICRO-HOPE. Diabetes/Metab. Res. Rev. 2002, 18, S82–S85. [Google Scholar] [CrossRef] [PubMed]
  73. Hermida, R.C.; Ayala, D.E.; Mojón-Ojea, A.; Fernández, J.R. Influence of circadian time of hypertension treatment on cardiovascular risk: Results of the MAPEC study. Chronobiol. Int. 2010, 27, 1629–1651. [Google Scholar] [CrossRef] [PubMed]
  74. Hermida, R.C.; Crespo, J.J.; Domínguez-Sardiña, M.; Otero, A.; Moyá, A.; Ríos, M.T.; Sineiro, E.; Castiñeira, M.C.; A Callejas, P.; Pousa, L.; et al. Bedtime hypertension treatment improves cardiovascular risk reduction: The Hygia Chronotherapy Trial. Eur. Hear. J. 2020, 41, 4565–4576. [Google Scholar] [CrossRef]
  75. Xie, Z.; Zhang, J.; Wang, C.; Yan, X. Chronotherapy for morning blood pressure surge in hypertensive patients: A systematic review and meta-analysis. BMC Cardiovasc. Disord. 2021, 21, 274. [Google Scholar] [CrossRef]
  76. Chow, C.K.; Teo, K.K.; Rangarajan, S.; Islam, S.; Gupta, R.; Avezum, A.; Bahonar, A.; Chifamba, J.; Dagenais, G.; Diaz, R.; et al. Prevalence, Awareness, Treatment, and Control of Hypertension in Rural and Urban Communities in High-, Middle-, and Low-Income Countries. JAMA 2013, 310, 959–968. [Google Scholar] [CrossRef] [Green Version]
  77. Lindholt, J.S.; Søgaard, R. Population screening and intervention for vascular disease in Danish men (VIVA): A randomised controlled trial. Lancet 2017, 390, 2256–2265. [Google Scholar] [CrossRef]
  78. Altunkeser, B.B.; Avci, A.; Demir, K.; Kaya, Z.; Marakoglu, K.; Ceylan, E.; Ekmekci, A.H.; Yilmaz, M.B.; Demir, A. Arterial Stiffness and Carotid Intima-Media Thickness in Diabetic Peripheral Neuropathy. Med. Sci. Monit. Int. Med. J. Exp. Clin. Res. 2014, 20, 2074–2081. [Google Scholar] [CrossRef] [Green Version]
  79. Wang, S.; Randall, D.C.; Knapp, C.F.; Patwardhan, A.R.; Nelson, K.R.; Karounos, D.G.; Evans, J.M. Blood pressure regulation in diabetic patients with and without peripheral neuropathy. Am. J. Physiol. Integr. Comp. Physiol. 2012, 302, R541–R550. [Google Scholar] [CrossRef] [Green Version]
  80. Lambadiari, V.; Triantafyllou, K.; Dimitriadis, G.D. Insulin action in muscle and adipose tissue in type 2 diabetes: The significance of blood flow. World J. Diabetes 2015, 6, 626–633. [Google Scholar] [CrossRef]
Nutrients 15 00072 g001 550
Figure 1. Schematic association of antidiabetic medication and DPN status.
Figure 1. Schematic association of antidiabetic medication and DPN status.
Nutrients 15 00072 g001
Nutrients 15 00072 g002 550
Figure 2. Schematic presentation of antihypertensive therapy and DPN status.
Figure 2. Schematic presentation of antihypertensive therapy and DPN status.
Nutrients 15 00072 g002
Nutrients 15 00072 g003 550
Figure 3. Individuals with T2DM under no antihypertensive medication.
Figure 3. Individuals with T2DM under no antihypertensive medication.
Nutrients 15 00072 g003
Table
Table 1. Demographic, clinical, and biochemical characteristics of participants with diabetes. Results are shown as mean with SD in parentheses, unless indicated otherwise.
Table 1. Demographic, clinical, and biochemical characteristics of participants with diabetes. Results are shown as mean with SD in parentheses, unless indicated otherwise.
CharacteristicsTotal
n = 102		Absent/Mild
DPN
n = 54		Moderate/
Severe DPN
n = 48		p-Value
Sex, n (%) 0.111 1
Males64 (62.75)30 (55.56)34 (70.83)
Females38 (37.25)24 (44.44)14 (29.17)
Age (years)60.45 (±11.3)61.91 (±11.37)58.81 (±11.12)0.1687 2
BMI (kg/m2)30.37 (±5.94)28.78 (±4.39)32.1 (±6.9)0.0047 2
Duration of HTN (years)6.88 (±8.7)8.07 (±9.59)5.54 (±7.45)0.1432 2
Duration of DΜ (years)14.03 (±9.84)13.94 (±10.08)14.13 (±9.67)0.9268 2
DM Type, n (%)
T1DM7 (6.86)2 (3.70)5 (10.42)0.181 1
T2DM95 (93.10)52 (96.30)43 (89.58)
HbA1c (%)7.65 (±1.76)7.29 (±1.36)8.05 (±2.07)0.0306 2
1: p-values from Pearson’s X2 test; 2: p-value from two-sample t-test; mean (SD): mean (standard deviation); n: number of patients; HTN: hypertension; HbA1c: glycated hemoglobin; DM: diabetes mellitus; BMI: body mass index; T1DM: type 1 diabetes; T2DM: type 2 diabetes; DPN: diabetic peripheral neuropathy.
Table
Table 2. Independent-sample t-tests for variables of the 24 h ABPM analysis. Results are presented as mean ± SD (in parentheses). SBP: systolic blood pressure; DBP: diastolic blood pressure; 24 h ABPM:24 h ambulatory blood pressure monitoring; DPN: diabetic peripheral neuropathy.
Table 2. Independent-sample t-tests for variables of the 24 h ABPM analysis. Results are presented as mean ± SD (in parentheses). SBP: systolic blood pressure; DBP: diastolic blood pressure; 24 h ABPM:24 h ambulatory blood pressure monitoring; DPN: diabetic peripheral neuropathy.
24 h ABPM (mmHg)Total
n = 102		Absent/
Mild DPN
n = 54		Moderate/
Severe DPN
n = 48		p-Value
24 h SBP123.47 (11.92)121.96 (12.46)125.17 (11.17)0.1767
24 h DBP71.23 (7.45)69.59 (7.06)73.06 (7.52)0.0181
Daytime SBP125.4 (11.44)124.5 (12.02)126.42 (10.77)0.4009
Daytime DBP73.32 (7.21)72.24 (7.05)74.54 (7.26)0.1079
Nighttime SBP117.39 (16.76)114.14 (17.5)121.44 (15.04)0.0371
Nighttime DBP64.63 (9.45)62.33 (8.5)67.49 (9.88)0.0085
Table
Table 3. Results of Pearson’s X2 test for variables of the 24 h ABPM analysis.
Table 3. Results of Pearson’s X2 test for variables of the 24 h ABPM analysis.
24 h ABPMTotal
n = 102		Absent/
Mild DPN
n = 54		Moderate/
Severe DPN
n = 48		p-Values
24 h HTN stages, n (%)
<120/<8037 (36.27)21 (38.89)16 (33.33)0.854
120–129 and /80–8431 (30.39)17 (31.48)14 (29.17)
130–139 or /85–8924 (23.53)11 (20.37)13 (27.08)
>140 or /9010 (9.8)5 (9.26)5 (10.42)
ABPM patterns, n (%)0.323
No extra pattern57 (55.88)32 (59.26)25 (52.08)
WCH37 (36.27)16 (29.63)21 (43.75)
Masked HTN7 (6.86)5 (9.26)2 (4.17)
ABPM dipping status, n (%)0.061
Dippers36 (37.5)24 (47.06)12 (26.67)
Non-dippers36 (37.5)14 (27.45)22 (48.89)
Reverse dippers24 (25)13 (25.49)11 (24.44)
HTN: hypertension, ABPM: ambulatory blood pressure monitoring; DPN: diabetic peripheral neuropathy; WCH: white coat hypertension.
Table
Table 4. Odds ratios (OR) and 95% confidence intervals (CI) for the association between stages of DPN and HTN.
Table 4. Odds ratios (OR) and 95% confidence intervals (CI) for the association between stages of DPN and HTN.
Univariate ModelMultivariate Model
VariablesOR95% CIp-ValueOR95% CIp-Value
Age (in years)0.98(0.94–1.01)0.1690.98(0.94–1.02)0.335
Sex
Females vs. Males0.51(0.23–1.17)0.1130.35(0.14–0.92)0.033
Smoking
Yes vs. No1.75(0.73–4.21)0.212
ΒΜΙ1.11(1.02–1.20) 0.008
HTN (years)0.96(0.92–1.01)0.148
DM (years)1.00(0.96–1.04)0.926
HbA1c (%)1.30(1.02–1.66)0.037
No. of antihypertensives vs. no. medication
10.64(0.20–2.05)0.448
20.73(0.23–2.27)0.583
>20.5(0.19–1.33)0.164
Type of antidiabetic vs. diet
Tablets0.22(0.02–2.29)0.206
Insulin0.21(0.18–2.47)0.215
Oral agents and Insulin0.5(0.04–5.40)0.568
ABPM dipping
Non-dippers vs. dippers3.14(1.19–8.24)0.023.93(1.33–11.64)0.013
Reverse dippers1.69(0.59–4.88)0.3311.74(0.54–5.65)0.354
ABPM status
Hypertensives vs. Normotensives1.43(0.64–3.20)0.386
24 h SBP1.02(0.99–1.06)0.177
24 h DBP1.07(1.00–1.13)0.022
Daytime SBP1.02(0.98–1.05)0.397
Daytime DBP1.05(0.99–1.11)0.11
Nighttime SBP1.03(1.00–1.06)0.042
Nighttime DBP1.06(1.01–1.12)1,012
24 h-Hypertension stages
<120/<80Reference categoryReference category
120–129 and/80–841.08(0.41–2.82)0.8740.89(0.30–2.69)0.848
130–139 or /85–891.55(0.32–5.32)0.4050.95(0.29–3.14)0.932
140 or /901.31(0.32–5.32)0.7031.18(0.23–5.99)0.843
OR: odds ratio, 95% CI: 95% confidence interval, SBP: systolic blood pressure, DBP: diastolic blood pressure, HTN: hypertension, DM: diabetes mellitus, ABPM: ambulatory blood pressure monitoring; SBP: systolic blood pressure; DBP: diastolic blood pressure; HbA1c: glycated hemoglobin.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Ntavidi, S.; Katsanou, P.; Marakomichelakis, G.; Kasdagli, M.-I.; Antiochou, E.; Mpali, I.; Kakou, A.-M.; Tsioufis, K.; Dimitriadis, G.; Lambadiari, V. Association of Non-Dipping Blood Pressure Patterns with Diabetic Peripheral Neuropathy: A Cross-Sectional Study among a Population with Diabetes in Greece. Nutrients 2023, 15, 72. https://doi.org/10.3390/nu15010072

AMA Style

Ntavidi S, Katsanou P, Marakomichelakis G, Kasdagli M-I, Antiochou E, Mpali I, Kakou A-M, Tsioufis K, Dimitriadis G, Lambadiari V. Association of Non-Dipping Blood Pressure Patterns with Diabetic Peripheral Neuropathy: A Cross-Sectional Study among a Population with Diabetes in Greece. Nutrients. 2023; 15(1):72. https://doi.org/10.3390/nu15010072

Chicago/Turabian Style

Ntavidi, Styliani, Panagiota Katsanou, George Marakomichelakis, Maria-Iosifina Kasdagli, Eleni Antiochou, Ioulia Mpali, Anda-Monica Kakou, Konstantinos Tsioufis, George Dimitriadis, and Vaia Lambadiari. 2023. "Association of Non-Dipping Blood Pressure Patterns with Diabetic Peripheral Neuropathy: A Cross-Sectional Study among a Population with Diabetes in Greece" Nutrients 15, no. 1: 72. https://doi.org/10.3390/nu15010072

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop